Evidence map›Paper›PMID 38153436›Full record

ArticleMolecular cancer research : MCR2024

FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer.

Eylem Kulkoyluoglu Cotul, Muhammad Hassan Safdar, Sebastian Juan Paez, Aneesha Kulkarni, Mitchell G Ayers, Hang Lin, Zilin Xianyu, Dorothy Teegarden, Stephen D Hursting, Michael K Wendt

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Eylem Kulkoyluoglu CotulDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0003-2398-2441
Muhammad Hassan SafdarDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-2553-1268
Sebastian Juan PaezDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-0065-1474
Aneesha KulkarniDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0001-8770-9925
Mitchell G AyersDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0003-4049-9013
Hang LinDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-4824-3146
Zilin XianyuDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0009-0002-4216-0646
Dorothy TeegardenPurdue University Institute for Cancer Research, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-7045-3748
Stephen D HurstingLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-3605-2833
Michael K WendtDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.ORCID 0000-0002-3665-7413
Purdue University West Lafayette · USUniversity of North Carolina at Chapel Hill · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Obesity, Metabolism and Breast Cancer MetastasisR01CA232589 · NCI · PURDUE UNIVERSITY · PI HURSTING, STEPHEN D, TEEGARDEN, DOROTHY · 2019 to 2023
$2.6M
Impact of hypoxia on lipid metabolism in obesity-driven breast cancer progressionR01CA271597 · NCI · PURDUE UNIVERSITY · PI Stephen D Hursting, Dorothy Teegarden · 2023 to 2026
$2.5M
The influence of alcohol on the metastatic dormancy of breast cancerR21AA026675 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M., WENDT, MICHAEL KEITH · 2018 to 2019
$280k
NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA232589NCI NIH HHS R01 CA271597NIAAA NIH HHS R21 AA026675
6 · The paper itself

Abstract

Survival of dormant, disseminated breast cancer cells contributes to tumor relapse and metastasis. Women with a body mass index greater than 35 have an increased risk of developing metastatic recurrence. Herein, we investigated the effect of diet-induced obesity (DIO) on primary tumor growth and metastatic progression using both metastatic and systemically dormant mouse models of breast cancer. This approach led to increased PT growth and pulmonary metastasis. We developed a novel protocol to induce obesity in Balb/c mice by combining dietary and hormonal interventions with a thermoneutral housing strategy. In contrast to standard housing conditions, ovariectomized Balb/c mice fed a high-fat diet under thermoneutral conditions became obese over a period of 10 weeks, resulting in a 250% gain in fat mass. Obese mice injected with the D2.OR model developed macroscopic pulmonary nodules compared with the dormant phenotype of these cells in mice fed a control diet. Analysis of the serum from obese Balb/c mice revealed increased levels of FGF2 as compared with lean mice. We demonstrate that serum from obese animals, exogenous FGF stimulation, or constitutive stimulation through autocrine and paracrine FGF2 is sufficient to break dormancy and drive pulmonary outgrowth. Blockade of FGFR signaling or specific depletion of FGFR1 prevented obesity-associated outgrowth of the D2.OR model. IMPLICATIONS: Overall, this study developed a novel DIO model that allowed for demonstration of FGF2:FGFR1 signaling as a key molecular mechanism connecting obesity to breakage of systemic tumor dormancy and metastatic progression.

Indexed as

Breast NeoplasmsAnimalsFemaleFibroblast Growth Factor 2HumansMiceMice, Inbred BALB CNeoplasm Recurrence, LocalObesityReceptor, Fibroblast Growth Factor, Type 1Signal TransductionFGFR1 protein, humanFibroblast Growth Factor 2Receptor, Fibroblast Growth Factor, Type 1

Identifiers

PMID38153436
PMCPMC10923021
OpenAlexW4390348060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.